-
1
-
-
33644618433
-
The biology of incretin hormones
-
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153-165.
-
(2006)
Cell Metab
, vol.3
, Issue.3
, pp. 153-165
-
-
Drucker, D.J.1
-
2
-
-
35748957503
-
The physiology of glucagon-like peptide 1
-
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
-
(2007)
Physiol Rev
, vol.87
, Issue.4
, pp. 1409-1439
-
-
Holst, J.J.1
-
3
-
-
3242730474
-
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
-
Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-E206.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
, Issue.2
-
-
Holst, J.J.1
Gromada, J.2
-
4
-
-
0023758530
-
Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach
-
Orskov C, Holst JJ, Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009-2013.
-
(1988)
Endocrinology
, vol.123
, Issue.4
, pp. 2009-2013
-
-
Orskov, C.1
Holst, J.J.2
-
5
-
-
0036959991
-
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
-
Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, Issue.3
, pp. 1239-1246
-
-
Nauck, M.A.1
Heimesaat, M.M.2
Behle, K.3
-
6
-
-
0030667056
-
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
-
Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 pt 1):E981-E988.
-
(1997)
Am J Physiol
, vol.273
, Issue.5 PART 1
-
-
Nauck, M.A.1
Niedereichholz, U.2
Ettler, R.3
-
7
-
-
0029859220
-
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
-
Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271(4 pt 2):R848-R856.
-
(1996)
Am J Physiol
, vol.271
, Issue.4 PART 2
-
-
Tang-Christensen, M.1
Larsen, P.J.2
Göke, R.3
-
8
-
-
79956336447
-
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
-
Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab. 2011;96(6):1763-1770.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, Issue.6
, pp. 1763-1770
-
-
Cersosimo, E.1
Gastaldelli, A.2
Cervera, A.3
-
9
-
-
45549101449
-
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
-
Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846-E852.
-
(2008)
Am J Physiol Endocrinol Metab
, vol.294
, Issue.5
-
-
Cervera, A.1
Wajcberg, E.2
Sriwijitkamol, A.3
-
10
-
-
0038497464
-
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
-
Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, Issue.7
, pp. 3082-3089
-
-
Kolterman, O.G.1
Buse, J.B.2
Fineman, M.S.3
-
11
-
-
0033151448
-
Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro
-
Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20(11):1057-1062.
-
(1999)
Biomaterials
, vol.20
, Issue.11
, pp. 1057-1062
-
-
Tracy, M.A.1
Ward, K.L.2
Firouzabadian, L.3
-
12
-
-
80052731231
-
Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes
-
DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.
-
(2011)
Diabetes Technol Ther
, vol.13
, Issue.11
, pp. 1145-1154
-
-
Deyoung, M.B.1
Macconell, L.2
Sarin, V.3
Trautmann, M.4
Herbert, P.5
-
13
-
-
79960952161
-
AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: Executive summary
-
Handelsman Y, Mechanick JI, Blonde L, et al; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17(2):287-302.
-
(2011)
Endocr Pract
, vol.17
, Issue.2
, pp. 287-302
-
-
Handelsman, Y.1
Mechanick, J.I.2
Blonde, L.3
-
14
-
-
84866268783
-
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
15
-
-
53249142132
-
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
-
DURATION-1 Study Group
-
Drucker D, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
-
(2008)
Lancet
, vol.372
, Issue.9645
, pp. 1240-1250
-
-
Drucker, D.1
Buse, J.B.2
Taylor, K.3
-
16
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
DURATION-2 Study Group
-
Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.
-
(2010)
Lancet
, vol.376
, Issue.9739
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
-
17
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
-
Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
-
(2010)
Lancet
, vol.375
, Issue.9733
, pp. 2234-2243
-
-
Diamant, M.1
van Gaal, L.2
Stranks, S.3
-
18
-
-
84859013614
-
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): A 26-week, double-blind study
-
DURATION-4 Study Group
-
Russell-Jones D, Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week, double-blind study. Diabetes Care. 2012;35(2):252-258.
-
(2012)
Diabetes Care
, vol.35
, Issue.2
, pp. 252-258
-
-
Russell-Jones, D.1
Cuddihy, R.M.2
Hanefeld, M.3
-
19
-
-
79955661908
-
DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes
-
Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, Issue.5
, pp. 1301-1310
-
-
Blevins, T.1
Pullman, J.2
Malloy, J.3
-
20
-
-
84857385645
-
Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): A randomised, open-label study [abstract 75]
-
Buse B, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract 75]. Diabetologia. 2011;54(suppl 1):S38.
-
(2011)
Diabetologia
, vol.54
, Issue.SUPPL. 1
-
-
Buse, B.1
Nauck, M.A.2
Forst, T.3
-
21
-
-
84887412474
-
Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes
-
Ji LN, Onishi Y, Woo AC, et al. Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes. World Diabetes Congress Abstract Book. 2011; P1144.
-
(2011)
World Diabetes Congress Abstract Book
-
-
Ji, L.N.1
Onishi, Y.2
Woo, A.C.3
-
22
-
-
84876524541
-
-
BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc
-
BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012.
-
(2012)
-
-
-
23
-
-
0033578476
-
Pharmacologic therapy for type 2 diabetes mellitus
-
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303.
-
(1999)
Ann Intern Med
, vol.131
, Issue.4
, pp. 281-303
-
-
Defronzo, R.A.1
-
24
-
-
16344382941
-
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study
-
Matthews DR Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167-174.
-
(2005)
Diabetes Metab Res Rev
, vol.21
, Issue.2
, pp. 167-174
-
-
Matthews, D.R.1
Charbonnel, B.H.2
Hanefeld, M.3
Brunetti, P.4
Schernthaner, G.5
-
25
-
-
77955900074
-
Effects of thiazolidinediones and sulfonylureas in patients with diabetes
-
Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12(6):491-501.
-
(2010)
Diabetes Technol Ther
, vol.12
, Issue.6
, pp. 491-501
-
-
Derosa, G.1
Maffioli, P.2
-
26
-
-
0032511583
-
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 837-853
-
-
-
27
-
-
84859879074
-
Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide
-
Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract. 2012;18(2):227-237.
-
(2012)
Endocr Pract
, vol.18
, Issue.2
, pp. 227-237
-
-
Pencek, R.1
Brunell, S.C.2
Li, Y.3
Hoogwerf, B.J.4
Malone, J.5
|